Based on the existing evidence, our study demonstrated that anti-PD1 therapy combination therapy (mainly with an antiangiogenic agent) is an effective and well-tolerated approach for unresectable HCC in the real world. Here, PDCD1 is linked to hepatocellular carcinoma.